A scientific statement from the American Heart Association was published in Circulation, with the purpose of providing a thorough review of available evidence on HIV-associated cardiovascular disease.
This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
Although the CDC recommends routine HIV screening for all people age 13-64 years, numerous barriers to HIV testing in healthcare settings have been identified, including lack of access and fear of stigma and discrimination.
Treatment with dolutegravir and either of 2 tenofovir prodrugs, tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, is noninferior to standard HIV antiretroviral regimes.
Focusing on interventions that address high-risk sexual behaviors and injection practices may reduce HIV transmission rates among individuals who are HIV-positive and inject drugs, according to study results published in the Centers for Disease Control and Prevention (CDC)’s Morbidity and Mortality Weekly Report. Researchers used a 2-stage sampling method to evaluate injection practices, sexual behaviors, and…
Janssen announced positive top-line results from the phase 3 ATLAS-2M study evaluating the two-drug long-acting injectable regimen of rilpivirine (Janssen) and cabotegravir (ViiV Healthcare) administered every 2 months in patients with HIV-1 infection.
Evidence on intervention effectiveness in improving uptake and retention of mothers and infants in the prevention of mother-to-child transmission care in HIV regimens is lacking.
Elderly patients with HIV who have cancer, and specifically breast and prostate cancer, may have worse outcomes when compared with elderly patients without HIV with cancer.
The risk of sudden cardiac death was present across all strata of left ventricular ejection fraction and was related to the use of cocaine, lower use of beta-blockers, lower CD4, and nonsuppressed viral load.
In the NAMSAL ANRS 12313 trial, investigators compared a dolutegravir-based regimen with a low-dose efavirenz-based regimen for the treatment of HIV-1 infection.
Human immunodeficiency virus treatment may be improved in incarcerated individuals with interdisciplinary academic medical care delivered via telemedicine.
